NMRA250117C3000
- 0.04
- 0.000.00%
Neumora Therapeutics Newsroom
Neumora Therapeutics Highlights Progress at Healthcare Conference
Neumora Therapeutics Shares Are Trading Higher. B of A Securities Maintained a Buy Rating on the Stock.
B of A Securities Maintains Buy on Neumora Therapeutics, Lowers Price Target to $7
Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA) and Idexx Laboratories (IDXX)
Trending Stocks as Wall Street Steps Into First Days of 2025 With Cautiousness
Sector Update: Health Care Stocks Higher Friday Afternoon
Neumora Therapeutics Up Over 16%, on Pace for Largest Percent Increase Since December 2023 -- Data Talk
Neumora Has 2 More Chances With Navacaprant After Readout Miss, Mizuho Says
Rivian Automotive, Cerence, Nu Skin Enterprises And Other Big Stocks Moving Higher On Friday
J.P. Morgan Maintains Neumora Therapeutics(NMRA.US) With Hold Rating
Mizuho Securities Maintains Neumora Therapeutics(NMRA.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Natera (NTRA) and Neumora Therapeutics, Inc. (NMRA)
A Quick Look at Today's Ratings for Neumora Therapeutics(NMRA.US), With a Forecast Between $23 to $30
Neumora Therapeutics Selloff Seen as Overdone -- Market Talk
Neumora Therapeutics' Navacaprant Did Not Meet Primary Endpoint in Depression
Hold Rating for Neumora Therapeutics Amid Disappointing Phase 3 Trial Results and High-Risk Pipeline Dependency
Neumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - NMRA
U.S. Small Caps Close Mixed As Rigetti Computing Lead, Neumora Therapeutics Lags
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Sector Update: Health Care Stocks Softer Late Afternoon